RCS - Redx Pharma plc - Redx to Present at the ECM Congress

Redx PharmaAnnouncement

20/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220620:nRST3866Pa&default-theme=true

RNS Number : 3866P  Redx Pharma plc  20 June 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx to Present Preclinical Data on Three Proprietary Compounds at the
Extracellular Matrix Pharmacology Congress

 

Alderley Park, 20 June 2022 Redx (AIM: REDX), the clinical-stage biotechnology
company focused on discovering and developing novel, small molecule, highly
targeted therapeutics for the treatment of cancer and fibrotic disease, today
announces that preclinical data from three of the Company's proprietary
compounds will be presented at the Extracellular Matrix Pharmacology Congress
("ECM"), being held in Copenhagen, Denmark, 23rd-25th June 2022. The two
presentations cover data originating from Redx collaborations with prestigious
international research institutes, the Garvan Institute of Medical Research
("the Garvan"), Australia and Ghent University, Belgium.

 

The first presentation will highlight preclinical data from Redx's ongoing
collaboration with the Garvan demonstrating the efficacy of targeting fibrosis
associated with pancreatic cancer in mouse models with Redx's Porcupine
inhibitor, RXC004, and a Redx proprietary ROCK2 selective inhibitor. The
second presentation will detail results from a research collaboration with
scientists at Ghent University assessing the efficacy of RXC008, a GI-targeted
ROCK inhibitor, to suppress fibrosis as measured by histopathology and
magnetic resonance imaging (MRI).

 

 Title:     Investigation of novel therapeutic targets in pancreatic cancer-associated
            fibrosis

 Day/Date:  Thursday 23 June 2022, 12:45 - 13:30 CEST

 Title:     RXC008 suppresses fibrosis in a DSS model as measured by histopathology and
            magnetic resonance imaging

 Day/Date:  Saturday 25 June 2022, 13:35 - 13:45 CEST

 

The final program is available on the ECM website at:
 https://ecm-congress.org/scientific-program/
(https://ecm-congress.org/scientific-program/)

 

About the Extracellular Matrix Pharmacology Congress

 

Redx is one of eight symposium sponsors of the ECM Congress, organised by the
Danish Research Foundation. The Congress will bring together experts in the
fields of cancer, fibrosis and immunology to discuss new pharmacological
approaches to treat chronic diseases often caused by alterations in the
extracellular matrix ("ECM") structure.

 

 For further information, please contact:

 Redx Pharma Plc                                             T: +44 (0)1625 469 918

 Caitlin Pearson, Head of Communications ir@redxpharma.com
 (mailto:ir@redxpharma.com)

 UK Headquarters

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                 T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                              T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                  T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                              T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's selective ROCK2 inhibitor product
candidate, RXC007, is in development for idiopathic pulmonary fibrosis and
commenced a Phase 1 clinical trial in June 2021. Encouraging safety and
pharmacokinetic data has been reported, and a Phase 2 clinical program is
confirmed to start in 2022. Redx's third drug candidate, RXC008, a GI-targeted
ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is
currently in pre-IND stage, with Phase 1 clinical studies expected to commence
in 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting
fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which
AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has
forged collaborations with Jazz Pharmaceuticals which includes JZP815, a
preclinical pan-RAF inhibitor which has received IND clearance, and further
oncology programmes which are in early stage research.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

About The Garvan Institute of Medical Research

The Garvan Institute of Medical Research brings together world leading
researchers and clinicians, collaborating locally and globally, to improve
human health. Our mission is to harness all the information encoded in our
genome to better diagnose, treat, predict and prevent disease. From the
individual patient with rare disease, to the many thousands affected by
complex, widespread illness, we are pioneering discoveries across diseases
that have the deepest impact on our community.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLMPTMTABBBT